Novus Therapeutics (NASDAQ:NVUS) Issues Quarterly Earnings Results

Novus Therapeutics (NASDAQ:NVUS) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.35) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.35), Bloomberg Earnings reports.

Shares of NVUS stock traded down $0.02 during mid-day trading on Wednesday, hitting $0.80. The company’s stock had a trading volume of 17,181 shares, compared to its average volume of 108,038. Novus Therapeutics has a 52-week low of $0.71 and a 52-week high of $5.78. The company has a 50-day moving average of $0.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.18 and a current ratio of 3.18. The firm has a market capitalization of $10.39 million, a PE ratio of -0.51 and a beta of 2.87.

Several equities research analysts have commented on NVUS shares. Zacks Investment Research raised Novus Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 28th. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $10.00 target price on shares of Novus Therapeutics in a report on Wednesday, May 15th. Finally, ValuEngine downgraded Novus Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, July 26th.

In other news, CEO Gregory J. Flesher sold 14,638 shares of the business’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $1.95, for a total value of $28,544.10. Following the completion of the transaction, the chief executive officer now owns 159,855 shares in the company, valued at $311,717.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 29,451 shares of company stock valued at $57,429 in the last 90 days. Company insiders own 5.70% of the company’s stock.

Novus Therapeutics Company Profile

Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection).

See Also: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Earnings History for Novus Therapeutics (NASDAQ:NVUS)

Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with's FREE daily email newsletter.